Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 80
SponsorPeking Union Medical College
About this trial
This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.
Eligibility criteria
Qualifiers
Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS
The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital
Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital
Patients with complete clinical data followed up for at least 1 year
Disqualifiers
Patients lost to follow-up
Patients with less than one year of follow-up
Patients who received additional adjuvant therapy during the follow-up period
Trial design
Treatments tested in this trial
- Surgery combined with secukinumab
Treatment groups
100 Participants
are divided into 1 treatment groupLocations
1Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College210042, NanjingJiangsu, China
Sponsors and collaborators
Peking Union Medical College
Lead sponsor
Source ClinicalTrials.gov